Company
Shanghai
Every published round Viva Biotech Holdings took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Viva Biotech Holdings has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Viva Biotech Holdings, as distinct from the investments it has made.
Companies Viva Biotech Holdings has backed that another company then bought. An exit for the holding, not a deal Viva Biotech Holdings did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| No portfolio company of Viva Biotech Holdings is recorded as having been acquired. | ||||
Companies Viva Biotech Holdings acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Company | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| SYNthesis Med Chem | Acquisition | 2020 | $123.6m | Forbes Australia, Synthesis BioVentures |
Stories naming Viva Biotech Holdings. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Biotech scientist Andrew Wilks launches fund SYNthesis BioVentures, which has gathered $20m and aims for $75m; his group has backed two biotech startups and he earlier sold a chemistry business to Viva Biotech.
Also Forbes Australia